canakinumab
novartis
['nsclc', 'canopy-a', 'sclc', 'medsir']
canopy-a: phase iii study did not show a dfs benefit with can vs pbo after surgery and adjuvant ctx in stage ii-iiib nsclc pts (mdfs 35.0 vs 29.7 mo; hr 0.94) by dr. #edwardgaron #esmo22 
Bring your idea to life??Creating successful IITs & optimal drug development??Medica Scientia Innovation Research????????https://t.co/cciUf0lqpM